相似文献
1
Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome.
J Neurol Neurosurg Psychiatry. 1998 Feb;64(2):148-9. doi: 10.1136/jnnp.64.2.148a.
2
Is there a scientific rationale for therapeutic plasma exchange or intravenous immune globulin in the treatment of acute Guillain-Barré syndrome?
J Clin Apher. 1995;10(3):150-7. doi: 10.1002/jca.2920100310.
3
Circulating transforming growth factor beta 1 (TGF-beta1) in Guillain-Barré syndrome: decreased concentrations in the early course and increase with motor function.
J Neurol Neurosurg Psychiatry. 1998 Feb;64(2):162-5. doi: 10.1136/jnnp.64.2.162.
4
Modulating the immune response in demyelinating diseases.
J Neurol Neurosurg Psychiatry. 1998 Feb;64(2):148. doi: 10.1136/jnnp.64.2.148.
5
Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. Dutch Guillain-Barré study group.
J Neurol Neurosurg Psychiatry. 1998 Feb;64(2):242-4. doi: 10.1136/jnnp.64.2.242.
6
Intravenous immunoglobulin versus plasma exchange in Guillain-Barré syndrome.
Neurology. 1993 Dec;43(12):2729; author reply 2730-1. doi: 10.1212/wnl.43.12.2729-a.
7
The Guillain-Barré syndrome: plasma exchange or immunoglobulins intravenously.
J Neurol Neurosurg Psychiatry. 1994 Nov;57 Suppl(Suppl):33-4. doi: 10.1136/jnnp.57.suppl.33.
8
Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange.
J Neurol Neurosurg Psychiatry. 1991 Nov;54(11):957-60. doi: 10.1136/jnnp.54.11.957.
9
The Guillain-Barré syndrome: plasma exchange or immunoglobulins intravenously?
Ann Med Interne (Paris). 1994;145(5):293-5.
10
Second response to immunoglobulin in recurrent Guillain-Barré syndrome.
N Z Med J. 1998 Nov 13;111(1077):433-4.
Zotero 插件